Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Future targets for pancreatic cancer treatment

Michael Kim • 8 Apr 2021
AACR 2021
Gastrointestinal Cancer Pancreatic Cancer

Michael Kim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the future of treatment for pancreatic cancer, highlighting potential targeting of pathways impacted by mutant p53 or oncogenic KRAS, such as CREB1, to prevent metastasis. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

More from Michael Kim

5:17
Mutant p53 and oncogenic KRAS drive metastasis in pancreatic cancer
Michael Kim • 8 Apr 2021

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals